

Index

A

- Activity regulation, 35–45
- Adenomatous polyposis coli (APC), 203–205, 223
- Akt
 - Akt2/PKB β , 126, 134, 135, 137
 - isoforms, 127, 134
- Allosteric communication, 29, 30
- α -subunit, 4, 5, 7, 9, 10, 12, 13, 36–41, 224, 243, 324, 328, 332, 365, 366, 370
- Anticancer peptides, 287, 296
- Antisense, 165, 173, 260, 301, 304
- APC. *See* Adenomatous polyposis coli (APC)
- Apoptosis, 8, 66, 111, 126, 142, 161, 162, 249, 259, 282, 301, 330, 352, 363
- Asf1, 3–13
- Asymmetric CK2 holoenzyme, 36–41
- ATP-competitive inhibitors, 324, 351, 367–370
- Autoinhibition, 35–45
- Autoinhibitory region, 8
- Autophosphorylation, 4, 7, 40, 41, 290, 314, 331, 346, 350

B

- Bak, 162
- Basic helix-loop-helix (bHLH), 84, 86, 88, 89, 91, 93, 95, 100
- Bax, 162, 166, 171
- Bcl-2, 162, 163, 166, 171–173, 218, 263, 265, 308
- Bcl-xL, 165, 166, 171, 263, 271, 308
- Beta(β) cells, 112–117, 119, 133

- bHLH. *See* Basic helix-loop-helix (bHLH)
- Bid, 163, 167, 363, 364
- Biomineralization, 235
- Bispecific oligonucleotides targeting CK2 α and CK2 α' , 307
- B23/nucleophosmin, 170, 283, 285, 287, 288, 294, 296, 302
- Bone, 230, 305
- Breast cancer. *See* Cancer, breast

C

- Cancer
 - breast, 129, 134, 142, 148, 149, 151–153, 170, 234, 242, 250, 254, 261, 262, 264, 269, 272, 301
 - renal, 241–255
 - therapy, 131, 168, 169, 172, 173, 296, 299–309
- The Cancer Genome Atlas (TCGA), 260
- Casein kinase 2 (CK2)
 - inhibitors, 9, 66, 91, 115, 116, 119, 129, 137, 151–153, 167, 168, 171, 172, 184, 191, 235, 242, 251, 255, 264–266, 271, 272, 286–288, 293, 301, 302, 305, 307, 319–336, 341–353, 364, 367, 368
 - subunits, 13, 50, 51, 111, 165, 187, 199, 205, 224, 229, 243, 247–249, 254, 260, 262, 273, 282, 365
- Casein kinases, 160, 228, 233, 235
- Caspase, 69, 162, 163, 166, 167, 169, 188–191, 249, 260, 265, 282, 347, 363
- Cell cycle, 65, 83, 188, 201–205, 208, 210, 211, 222, 223, 260, 285, 321, 343

Cell death, 159–173, 249, 251, 270, 282, 285, 300, 301, 321, 326, 364
 Cells (786-O cells), 243, 244, 246, 249–255
 cIAP1, 168, 169
 cIAP2, 168, 169, 263
 CIGB-300, 281–296, 302
 CK2 α p+1 loop, 36–38, 40
 CK2 β acidic loop, 22, 36, 38
 CK2 β C-terminal tail, 36, 40
 CK2-targeted therapy, 243, 281–296
 CMGC kinases, 342, 344, 346
 Constitutive activity, 4, 6, 18, 131, 189, 191, 266, 300, 343
 Crystal contacts, 41
 Crystal structure, 7, 20, 29, 30, 36–44
 CX-4945, 115, 116, 118, 242, 245, 249–255, 264–266, 269, 270, 282, 285, 286, 288, 293, 302, 344, 351, 353
 Cytochrome *c*, 162, 166, 171–173
 Cytokines, 162, 263, 264, 266–268, 271

D

Dentin matrix protein-4 (DMP4), 229, 231
 Down's syndrome, 347, 350–353
 DTP compound libraries, 319–336
 DYRK1A, 341–353

E

eIF5. *See* Eukaryotic translation initiation factor 5 (eIF5)
 Electrostatic interactions, 38
 Embryo, 50–52, 54, 60–63, 83, 84, 111
 Epithelial-mesenchymal transition (EMT), 147, 150–152, 243, 248, 254, 261
 EPKs. *See* Eukaryotic protein kinases (EPKs)
 E(spl), 65, 81–101
 Eukaryotic protein kinases (EPKs), 6, 18, 20, 21, 23, 25, 26, 28–30, 233
 Eukaryotic translation initiation factor 5 (eIF5), 201–203, 223

F

Fam20C, 229–235
 Filaments, 40, 41, 44, 45, 69, 72

G

GBM. *See* Glioblastoma (GBM)
 G-CK, 229–235
 Germ layers, 60
 Glioblastoma (GBM), 260, 261, 263, 266, 269–272
 Golgi apparatus, 229, 232, 234, 235

H

Hairy-E(spl)-like (HES), 81–101
 Head and neck squamous cell carcinoma (HNSCC), 265, 300, 301, 304, 305, 308, 309
 HES. *See* Hairy-E(spl)-like (HES)
 Hierarchical phosphorylation, 82, 110, 188–190
 Hinge region, 23, 26–30
 Histology, 60
 Homeostasis, 59–74, 142–145, 222, 223, 260, 363

I

Inflammation, 68, 70, 223, 264, 267, 268, 330
 Inhibitor of apoptosis proteins (IAPs), 168, 169, 173
 α/β Interfaces, 36–39, 42, 43
 Islet, 112, 115

J

JAK/STAT, 170, 252, 261, 262, 266–269, 272, 273

K

Kinase inhibitor, 184, 191
 Knockout, 60–63, 70, 110, 117, 198, 199, 260, 347, 362

L

Leukemia, 254, 260, 268, 272, 284, 286, 301, 331, 352–353, 364

M

Maize, 27, 49–54, 328
 MAPKs. *See* Mitogen-activated protein kinases (MAPKs)
 Mass spectrometry, 145, 150, 151, 201, 202, 205–208, 210–212, 217, 223, 229, 283, 284, 287
 Metastasis, 82, 148, 150–152, 244, 262–265, 268, 287, 290
 Mitochondrial apoptotic circuitry, 165, 171
 Mitochondrial membrane potential, 171–173
 Mitochondrial permeability transition, 162
 Mitogen-activated protein kinases (MAPKs), 90, 92–97, 99–101, 146, 148, 251, 268, 330, 346
 Morphology, 59, 62, 63, 71, 304, 334

N

- Nanocapsules, 303–309
- Nanoparticles, 303
- Neurogenesis, 84–88, 101
- NFAT. *See* Nuclear factor of activated T cells (NFAT)
- NF- κ B, 162, 165, 261–266, 268, 271–273, 301, 307, 308, 330
- Notch signaling, 65, 83–89, 97–101
- Nuclear factor of activated T cells (NFAT), 347, 352, 353
- Nuclear functions, 208, 210
- Nuclear speckles, 50–52, 54
- Nucleophosmin, 170, 283, 302

O

- Oligomerization, 35–45
- Oligonucleotides targeting CK2 $\alpha\alpha'$, 307
- Organ development, 59–74
- Organ function, 71, 72, 74

P

- Pancreas, 112, 119
- Phosphoinositide 3-kinase (PI3K), 68, 126–129, 135–137, 170, 249, 261, 262, 268, 284, 290, 321, 330
- Phosphorylation, 4, 18, 40, 49, 64, 82, 110, 126, 143, 164, 184, 201–203, 250, 260, 282, 300, 322, 341, 363
- Phosphosecretome, 230, 234
- Physiology, 59–74
- PI3K. *See* Phosphoinositide 3-kinase (PI3K)
- PKB, 126, 284, 290
- PKB/Akt isoforms, 126, 127, 134–135
- PML. *See* Promyelocytic leukemia gene (PML)
- Polyamines, 6, 7, 38, 185, 343
- Post-transcriptional regulation, 254
- Post-translational modifications, 89, 145, 153, 183–191, 208, 268
- Promyelocytic leukemia gene (PML), 132, 133, 170, 261
- Prostate, 111, 119, 164, 166, 283, 284, 300, 302, 308, 331, 364
- Prostate cancer, 40, 113, 161, 164–166, 168, 169, 171, 301, 306, 307, 309, 327, 334
- Protein complex, 3, 169, 188, 369, 371
- Protein kinase inhibitors, 235, 328, 334, 343, 344
- Protein-protein interactions, 5, 43, 89, 98, 131, 350
- Proteomics, 188, 190, 208–210, 223, 287

- PTEN, 68, 127–129, 170, 249, 260, 261, 284, 285, 296, 363

R

- Raine syndrome, 230, 235
- Reactive oxygen species (ROS), 171–173, 269, 321, 327, 330, 331, 364
- Regulation, 3, 18, 35–45, 49, 64, 82, 109–119, 125–137, 161, 184, 216, 254, 268, 300, 346, 363
- Renal cancer, 241–255
- Repressors, 65, 69, 91–101, 350
- RNA binding protein, 49–54, 208, 210, 212–214, 216, 220
- RNAi, 307
- ROS. *See* Reactive oxygen species (ROS)

S

- Ser129 Akt1, 129, 130, 134, 135, 167, 168, 284
- Serine/threonine, 3, 59, 184, 199, 242, 259, 363
- Signaling pathways, 66, 83, 84, 98, 131, 133, 162, 165, 167, 199, 210, 223, 242, 251, 252, 255, 259–273, 290, 301, 321, 329, 330
- Signal transduction pathways, 170, 369
- SLC39A7, 141, 154
- Small molecule compounds, 332
- Splicing regulators, 49, 50, 52
- Structural dynamics, 20
- Structural plasticity, 19–20, 28–29
- Sub-50 nm TBG nanocapsules, 303
- Survivin, 130, 168, 169, 249, 252
- Symmetric CK2 holoenzyme, 41–44

T

- Targeted therapy, 242, 281–296
- TBB. *See* 4,5,6,7-Tetrabrombenzotriazole (TBB)
- TBG-RNAi, 304, 307–309
- Tenfibgen (TBG), 302–304
- 4,5,6,7-Tetrabrombenzotriazole (TBB), 65, 113, 116, 165, 166, 168, 169, 171, 172, 265, 268, 269, 271, 282, 302, 324, 343, 344, 348, 353, 368–370
- $\alpha_2\beta_2$ Tetramer, 41, 43
- Transcription factor, 5, 50, 51, 64, 68–71, 98, 111, 112, 119, 151, 152, 215, 216, 262, 267, 268, 286, 347, 350, 363
- Trimeric CK2 holoenzyme, 41

V

von Hippel-Lindau (VHL), 242, 244, 245,
249, 250, 252–255

W

Wnt, 60, 83, 98, 170, 249–251, 261,
262, 343

Y

Yeast, 3–13, 50–52, 82, 83, 89, 100, 109, 110,
184, 198, 199, 228, 324, 343, 350, 362,
364–367, 369, 370

Z

Zinc signalling, 141–153
ZIP7, 143–153